Gigantism medical therapy: Difference between revisions

Jump to navigation Jump to search
Charmaine Patel (talk | contribs)
No edit summary
Irfan Dotani (talk | contribs)
No edit summary
 
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Gigantism}}
{{Gigantism}}
{{CMG}}
{{CMG}}; {{AE}}


Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
{{PleaseHelp}}


==Overview==
==Overview==
Line 17: Line 17:


Radiation has also been linked to learning disabilities, obesity, and emotional changes in children. Most experts will use radiation only if surgery and medication fail.
Radiation has also been linked to learning disabilities, obesity, and emotional changes in children. Most experts will use radiation only if surgery and medication fail.
==References==
==References==
{{Reflist|2}}


{{Reflist|2}}
[[Category:Needs content]]
[[Category:Growth disorders]]
[[Category:Human height]]
[[Category:Growth hormones]]
[[Category:Neuroendocrinology]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
{{WS}}
{{WH}}

Latest revision as of 14:39, 22 July 2016

Gigantism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gigantism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gigantism medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gigantism medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gigantism medical therapy

CDC on Gigantism medical therapy

Gigantism medical therapy in the news

Blogs on Gigantism medical therapy

Directions to Hospitals Treating Gigantism

Risk calculators and risk factors for Gigantism medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Medical Therapy

In pituitary tumors with well-defined borders, surgery is the treatment of choice and can cure many cases.

For situations in which surgery cannot completely remove the tumor, medication is the treatment of choice. The most effective medications are somatostatin analogs (such as octreotide or long-acting lanreotide), which reduce growth hormone release.

Dopamine agonists (bromocriptine mesylate, cabergoline) have also been used to reduce growth hormone release, but these are generally less effective. Pegvisomant, a medication that blocks the effect of growth hormone, may be used.

Radiation therapy has also been used to bring growth hormone levels to normal. However, it can take 5 - 10 years for the full effects to be seen and this almost always leads to low levels of other pituitary hormones.

Radiation has also been linked to learning disabilities, obesity, and emotional changes in children. Most experts will use radiation only if surgery and medication fail.

References

Template:WS Template:WH